GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced its participation in the Centurion One Capital 3rd Annual Bahamas Summit, scheduled for October 28-29, 2025, at the Rosewood Baha Mar Hotel in Nassau, Bahamas. Michael Breen, the Executive Chairman and CEO, will represent the company at this prominent event, where they will host one-on-one meetings for interested attendees.

GT Biopharma is focused on developing cutting-edge immuno-oncology therapeutics utilizing its proprietary TriKE® NK cell engager platform. This innovative technology aims to enhance the natural killer (NK) cells of a patient’s immune system, bolstering their ability to combat cancer. The company has secured an exclusive worldwide licensing agreement with the University of Minnesota, which enables it to further refine and commercialize therapies based on TriKE® technology.

As a player in the burgeoning field of immuno-oncology, GT Biopharma is at the forefront of developing therapies that could transform cancer treatment. The upcoming Bahamas Summit presents an important opportunity for the company to engage with investors, showcase its advancements, and discuss future prospects in the evolving market of cancer therapeutics.

In addition, GT Biopharma emphasizes caution regarding its forward-looking statements, which reflect its current expectations and aspirations but may be subject to numerous uncertainties and risks. Readers are advised to consider these factors as detailed in the company's filings with the Securities and Exchange Commission. For more information about the company and its innovative products, potential investors and stakeholders can visit the official website at gtbiopharma.com.

This event marks a significant occasion for GT Biopharma as it seeks to enhance visibility and foster investor relations within the health-focused investment community.

GT Biopharma, Inc. (NASDAQ: GTBP) is strategically positioning itself for growth in the competitive biopharmaceutical landscape through its participation in the Centurion One Capital 3rd Annual Bahamas Summit. This forum, scheduled from October 28–29, 2025, offers a critical platform for investor engagement and networking, allowing the company to showcase its proprietary TriKE® (Tri T-cell Engager) NK cell engager platform, which focuses on immuno-oncology therapies.

As a clinical stage company, GT Biopharma faces both opportunities and challenges. The ongoing development of its NK cell engager platform is a significant value driver, supporting the potential for innovative cancer therapies that harness the body’s immune system. The exclusive worldwide license agreement with the University of Minnesota further strengthens GT Biopharma’s position, enhancing its credibility and presenting a pathway for commercialization.

Investors attending the Bahamas Summit can expect to gain insights into GT Biopharma's current clinical trials and future prospects. Engaging directly with Michael Breen, the Executive Chairman and CEO, provides a unique opportunity to discuss strategy, expected milestones, and how the company plans to navigate regulatory pathways and market entry.

However, prospective investors should remain cautious and consider the inherent risks highlighted in the company's forward-looking statements. The biopharmaceutical sector is notoriously volatile, with stock performance influenced by regulatory approvals, clinical trial outcomes, and competitive pressures.

In summary, while GT Biopharma presents an intriguing opportunity with its innovative approach to cancer treatment, investors should weigh the benefits of potential growth against the associated risks. With upcoming investor meetings and significant presentations on the horizon, this is a timely moment to monitor the company's developments closely. Potential investors should conduct thorough due diligence before making investment decisions.